Servier Pharmaceuticals is attending the European Epilepsy Congress from September 5-6 to engage in meaningful dialogue around scientific advancements, emerging research, and innovative approaches to epilepsy treatment and management.

Servier Pharmaceuticals is a Boston-based, commercial-stage biopharmaceutical company. As the U.S. subsidiary of Servier Group, Servier is governed by a non-profit foundation, enabling the company to approach innovation with a long-term vision centered on the patient, free of influence from outside investors and short-term market pressures. Launched in the U.S. in 2018, Servier Pharmaceuticals is focused on advancing innovative therapies in oncology and neurology for patients living with difficult-to-treat diseases. In oncology, the company has built a portfolio of first- and best-in-class medicines designed to bring transformative precision therapies to more patients. Servier is expanding its neurology business with the same commitment to science, partnership, and patient-focused innovation. At Servier, we bring the patient voice into everything we do. We are dedicated to advancing meaningful therapeutic progress and improving outcomes for the patients and communities we serve.